Imagion Biosystems has announced “Notice of Annual General Meeting/Proxy Form.”
Click here to view the notice (726 KB pdf)
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce